nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2017-4-4-67-73nodgo-335Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL CASESNUT midline carcinoma – первый доказанный случай заболевания у ребенка в Республике БеларусьNUT midline carcinoma – the first proven case of a child in the Republic of BelarusПролесковскаяИ. В.ProleskovskayaI. V.

Республика Беларусь, 223053, Минская область, Минский район, Боровлянский с/с, д. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk district, Minsk region, 223053, Republic of Belarus

proleskai@mail.ruМихалевскаяТ. М.MikhalevskayaT. M.

Республика Беларусь, 223053, Минская область, Минский район, Боровлянский с/с, д. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk district, Minsk region, 223053, Republic of Belarus

АлейниковаО. В.AleinikovaO. V.

Республика Беларусь, 223053, Минская область, Минский район, Боровлянский с/с, д. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk district, Minsk region, 223053, Republic of Belarus

ГУ «РНПЦ ДОГИ» Министерства здравоохранения Республики БеларусьБеларусьRepublican Center for Pediatric Oncology, Hematology and ImmunologyBelarus201730122017446773Copyright © Пролесковская И.В., Михалевская Т.М., Алейникова О.В., 20172017Пролесковская И.В., Михалевская Т.М., Алейникова О.В.Proleskovskaya I.V., Mikhalevskaya T.M., Aleinikova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/335

NUT midline carcinoma (NMC) – это очень редкое, высоко злокачественное заболевание с определенной цитогенетической аномалией t(15;19)(q14;p13.1). Эта опухоль может  встречаться в течение всей жизни, к сожалению, большинство случаев характеризуется  наличием метастазов на момент постановки диагноза. Имеются четкие цитогенетические и  молекулярно-биологические критерии диагноза. В мире не существует определенных  стандартов терапии, обеспечивающих эффективное лечение данной патологии. Однако  наличие химерного онкогена, характеризующего опухоль, перспективно в плане поиска  таргетных препаратов в рамках международного сотрудничества. Также необходим сбор  информации об этом редком заболевании для ее анализа и выявления наиболее эффективного  метода терапии. В данной статье представлен разбор клинического случая NMC, впервые диагностированной у ребенка 9 лет в Республике Беларусь.

NUT midline carcinoma (NMC) is a very rare, highly malignant disease with a specific cytogenetic abnormality t(15;19)(q14;p13.1). This tumor can occur throughout life, unfortunately, most cases are  characterized by the presence of metastases at the time of  diagnosis. There are clear cytogenetic and molecular-biological  criterias for diagnosis. There are no specific standards of therapy  that provide effective treatment of this pathology in the world.  However, the presence of a chimeric oncogene characterizing the  tumor is promising in terms of targeting drug research in the  framework of international cooperation. It is also necessary to collect information about this rare disease to analyze it and to identify the  most effective therapy method. This article presents an analysis of  the clinical case of NMC, first diagnosed in a child of 9-yearsold in the Republic of Belarus.

NUT midline carcinomaклиникадиагностикадетиподходы к терапииNUT midline carcinomaclinicdiagnosischildrenapproaches to therapyReferencesFrench C.A. NUT midline carcinoma. Cancer Genet Cytogenet 2010;203(1):16–20. doi: 10.1016/j.cancergencyto.2010.06.007.French C.A. NUT midline carcinoma. Cancer Genet Cytogenet 2010;203(1):16–20. doi: 10.1016/j.cancergencyto.2010.06.007.French C. NUT midline carcinoma. Nat Rev Cancer 2014;14(3):149–50. doi: 10.1038/nrc3659.French C. NUT midline carcinoma. Nat Rev Cancer 2014;14(3):149–50. doi: 10.1038/nrc3659.Travis W.D., Brambilla E., Burke A.P. et al. WHO Classification of Tumours of Lung, Pleura, Thymus and Heart (4th edition). IARC: Lyon, 2015.Travis W.D., Brambilla E., Burke A.P. et al. WHO Classification of Tumours of Lung, Pleura, Thymus and Heart (4th edition). IARC: Lyon, 2015.French C.A., Rahman S., Walsh E.M. et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 2014;4(8):928–41. doi: 10.1158/2159-8290.CD-14-0014.French C.A., Rahman S., Walsh E.M. et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov 2014;4(8):928–41. doi: 10.1158/2159-8290.CD-14-0014.Kees U.R., Mulcahy M.T., Willoughby M.L. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol 1991;13(4):459–64. PMID: 1785673.Kees U.R., Mulcahy M.T., Willoughby M.L. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol 1991;13(4):459–64. PMID: 1785673.Kubonishi I., Takehara N., Iwata J. et al. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991;51(12):3327–8. PMID: 2040007.Kubonishi I., Takehara N., Iwata J. et al. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991;51(12):3327–8. PMID: 2040007.Stelow E.B. A review of NUT midline carcinoma. Head Neck Pathol 2011;5(1):31–5. doi: 10.1007/s12105-010-0235-x.Stelow E.B. A review of NUT midline carcinoma. Head Neck Pathol 2011;5(1):31–5. doi: 10.1007/s12105-010-0235-x.Shaikh F., Pagedar N., Awan O., McNeely P. Sinonasal NUT-Midline Carcinoma - A Multimodality Approach to Diagnosis, Staging and Post-Surgical Restaging. Cureus 2015;7(7):e288. doi: 10.7759/cureus.288.Shaikh F., Pagedar N., Awan O., McNeely P. Sinonasal NUT-Midline Carcinoma - A Multimodality Approach to Diagnosis, Staging and Post-Surgical Restaging. Cureus 2015;7(7):e288. doi: 10.7759/cureus.288.French C.A., Kutok J.L., Faquin W.C. et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22(20):4135–9. doi: 10.1200/JCO.2004.02.107.French C.A., Kutok J.L., Faquin W.C. et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22(20):4135–9. doi: 10.1200/JCO.2004.02.107.Shehata B.M., Steelman C.K., Abramowsky C.R. et al. NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary. Pediatr Dev Pathol 2010;13(6):481–5. doi: 10.2350/09-10-0727-CR.1.Shehata B.M., Steelman C.K., Abramowsky C.R. et al. NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary. Pediatr Dev Pathol 2010;13(6):481–5. doi: 10.2350/09-10-0727-CR.1.Ziai J., French C.A., Zambrano E. NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland. Head Neck Pathol 2010;4(2):163–8. doi: 10.1007/s12105-010-0174-6.Ziai J., French C.A., Zambrano E. NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland. Head Neck Pathol 2010;4(2):163–8. doi: 10.1007/s12105-010-0174-6.den Bakker M.A., Beverloo B.H., van den Heuvel-Eibrink M.M. et al. NUT mid - line carcinoma of the parotid gland with mesenchymal differentiation. Am J Surg Pathol 2009;33(8):1253–8. doi: 10.1097/PAS.0b013e3181abe120.den Bakker M.A., Beverloo B.H., van den Heuvel-Eibrink M.M. et al. NUT mid - line carcinoma of the parotid gland with mesenchymal differentiation. Am J Surg Pathol 2009;33(8):1253–8. doi: 10.1097/PAS.0b013e3181abe120.D’Souza J.N., Notz G., Bogdasarian R.N. et al. Orbital Involvement by NUT Midline Carcinoma. Ophthal Plast Reconstr Surg 2015;31(6):e147–50. doi: 10.1097/IOP.0000000000000179.D’Souza J.N., Notz G., Bogdasarian R.N. et al. Orbital Involvement by NUT Midline Carcinoma. Ophthal Plast Reconstr Surg 2015;31(6):e147–50. doi: 10.1097/IOP.0000000000000179.Tanaka M., Kato K., Gomi K. et al. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol 2012;36(3):381–8. doi: 10.1097/PAS.0b013e31824230a8.Tanaka M., Kato K., Gomi K. et al. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol 2012;36(3):381–8. doi: 10.1097/PAS.0b013e31824230a8.Mertens F., Wiebe T., Adlercreutz C., Mandahl N., French C.A. Successful treat - ment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer 2007;49(7):1015–7. doi: 10.1002/pbc.20755.Mertens F., Wiebe T., Adlercreutz C., Mandahl N., French C.A. Successful treat - ment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer 2007;49(7):1015–7. doi: 10.1002/pbc.20755.Ball A., Bromley A., Glaze S. et al. A rare case of NUT midline carcinoma. Gynecol Oncol Case Rep 2012;3:1–3. doi: 10.1016/j.gynor.2012.09.004.Ball A., Bromley A., Glaze S. et al. A rare case of NUT midline carcinoma. Gynecol Oncol Case Rep 2012;3:1–3. doi: 10.1016/j.gynor.2012.09.004.Harms A., Herpel E., Pfarr N. et al. NUT carcinoma of the thorax: Case report and review of the literature. Lung Cancer 2015;90(3):484–91. doi: 10.1016/j.lungcan.2015.10.001.Harms A., Herpel E., Pfarr N. et al. NUT carcinoma of the thorax: Case report and review of the literature. Lung Cancer 2015;90(3):484–91. doi: 10.1016/j.lungcan.2015.10.001.French C.A. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol 2010;63(6):492–6. doi: 10.1136/jcp.2007.052902.French C.A. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol 2010;63(6):492–6. doi: 10.1136/jcp.2007.052902.French C.A., Miyoshi I., Kubonishi I. et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63(2):304–7. PMID: 12543779.French C.A., Miyoshi I., Kubonishi I. et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63(2):304–7. PMID: 12543779.Bishop J.A., Westra W.H. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol 2012;36(8):1216–21. doi: 10.1097/PAS.0b013e318254ce54.Bishop J.A., Westra W.H. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol 2012;36(8):1216–21. doi: 10.1097/PAS.0b013e318254ce54.Stelow E.B., Bellizzi A.M., Taneja K. et al. NUT rearrangement in undifferenti - ated carcinomas of the upper aerodigestive tract. Am J Surg Pathol 2008;32(6):828–34. doi: 10.1097/PAS.0b013e31815a3900.Stelow E.B., Bellizzi A.M., Taneja K. et al. NUT rearrangement in undifferenti - ated carcinomas of the upper aerodigestive tract. Am J Surg Pathol 2008;32(6):828–34. doi: 10.1097/PAS.0b013e31815a3900.Bauer D.E., Mitchell C.M., Strait K.M. et al. Clinicopathologic features and longterm outcomes of NUT midline carcinoma. Clin Cancer Res 2012;18(20):5773–9. doi: 10.1158/1078-0432.CCR-12-1153.Bauer D.E., Mitchell C.M., Strait K.M. et al. Clinicopathologic features and longterm outcomes of NUT midline carcinoma. Clin Cancer Res 2012;18(20):5773–9. doi: 10.1158/1078-0432.CCR-12-1153.Fujioka N., French C.A., Cameron M.J., Kratzke R.A. Long-term survival of a patient with squamous cell carcinoma harboring NUT gene rearrangement. J Thorac Oncol 2010;5(10):1704–5. doi: 10.1097/JTO.0b013e3181ebaa20.Fujioka N., French C.A., Cameron M.J., Kratzke R.A. Long-term survival of a patient with squamous cell carcinoma harboring NUT gene rearrangement. J Thorac Oncol 2010;5(10):1704–5. doi: 10.1097/JTO.0b013e3181ebaa20.Engleson J., Soller M., Panagopoulos I. et al. Midline carcinoma with t(15;19) and BRD4- NUT fusion oncogene in a 30-yearold female with response to docetaxel and radiotherapy. BMC Cancer 2006;6:69. doi: 10.1186/1471-2407-6-69.Engleson J., Soller M., Panagopoulos I. et al. Midline carcinoma with t(15;19) and BRD4- NUT fusion oncogene in a 30-yearold female with response to docetaxel and radiotherapy. BMC Cancer 2006;6:69. doi: 10.1186/1471-2407-6-69.Santis G, Landau D, Harrison-Phipps K., Neat M., Moonim M.T. Successful radical treatment of midline carcinoma with t(15;19) diagnosed by endobronchial ultrasound- derived transbronchial needle aspiration. J Clin Oncol 2011;29(12):e327–9. doi: 10.1200/JCO.2010.32.7973.Santis G, Landau D, Harrison-Phipps K., Neat M., Moonim M.T. Successful radical treatment of midline carcinoma with t(15;19) diagnosed by endobronchial ultrasound- derived transbronchial needle aspiration. J Clin Oncol 2011;29(12):e327–9. doi: 10.1200/JCO.2010.32.7973.French C.A. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247–65. doi: 10.1146/annurev- pathol-011811-132438.French C.A. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247–65. doi: 10.1146/annurev- pathol-011811-132438.Schwartz B.E., Hofer M.D., Lemieux M.E. et al. Differentiation of NUT midline car - cinoma by epigenomic reprogramming. Cancer Res 2011;71(7):2686–96. doi: 10.1158/0008-5472.CAN-10-3513.Schwartz B.E., Hofer M.D., Lemieux M.E. et al. Differentiation of NUT midline car - cinoma by epigenomic reprogramming. Cancer Res 2011;71(7):2686–96. doi: 10.1158/0008-5472.CAN-10-3513.Filippakopoulos P., Qi J., Picaud S. et al. Selective inhibition of BET bromodomains. Nature 2010;468(7327):1067–73. doi: 10.1038/nature09504.Filippakopoulos P., Qi J., Picaud S. et al. Selective inhibition of BET bromodomains. Nature 2010;468(7327):1067–73. doi: 10.1038/nature09504.Abazid N., Friemann J., Alfke H., Büttner R., Friedrichs N. NUT midline carcinoma: Two case reports and review of the literature. Adv Rare Dis 2016;3:1–10. doi:10.12715/ard.2014.3.1.Abazid N., Friemann J., Alfke H., Büttner R., Friedrichs N. NUT midline carcinoma: Two case reports and review of the literature. Adv Rare Dis 2016;3:1–10. doi:10.12715/ard.2014.3.1.

The authors declare that there are no conflicts of interest present.